Chantal elects new board member.LOS ANGELES--(BUSINESS WIRE)--June 6, 1996--Chantal Pharmaceutical Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CHTL) today announced that Norman F. Estrin, Ph.D., RAC See remote access concentrator. , a 25-year veteran of the cosmetic industry, has been elected to the company's board of directors. The announcement was made by Chantal Burnison, chairman and chief executive officer. This is the first in a series of steps that the company is taking to strengthen both its board and management, said Ms. Burnison. "Dr. Estrin's extensive experience, both domestically and internationally, and superb qualifications will be particularly valuable as the Company expands the marketing and distribution of its Ethocyn-based cosmetic products into the global marketplace," she said. Dr. Estrin has already been working with and will continue to serve as a consultant to the company, specifically with respect to the company's product launched into the Pacific Rim and other worldwide markets. Dr. Estrin assists pharmaceutical, cosmetic and other companies in executing international marketing and distribution programs, including structuring and negotiating licensing and distribution arrangements, and in complying with FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other government regulatory requirements, including regulatory submissions. In addition, he serves as a consultant to government agencies, medical conference planning organizations and an international marketing management company. Dr. Estrin conceived, developed and edited several internationally recognized text books in the cosmetic industry, and is currently editing a new book, Cosmetic Regulation in a Competitive Environment. Dr. Estrin brings to Chantal Pharmaceutical extensive expertise in the cosmetic industry, having held several management positions, including Senior Vice President-Science, at The Cosmetic, Toiletry and Fragrance Association from 1968 through 1985. While at CTFA CTFA Cosmetic, Toiletry, and Fragrance Association CTFA Certified Trust and Financial Advisor CTFA Canadian Table of Frequency Allocations CTFA Certificate in Teaching French to Adults , he created and edited the Cosmetic Ingredient Dictionary, which is recognized by the Food and Drug Administration and internationally as the official compendium official compendium Clinical pharmacology The US Pharmacopoeia, National Formulary or supplement thereto for ingredient labeling. Dr. Estrin left CFTA CFTA Canada Free Trade Agreement CFTA Cosmetic, Toiletry and Fragrance Association CFTA Culture and Free Thought Association CFTA Center for the Arts CFTA Chile Free Trade Agreement CFTA CDs-From-The-Artist dot com (music website) in 1985 to assume the position of Vice President - Science and Technology at the Health Industry Manufacturers Association, where he developed a number of international and domestic programs relating to the medical device industry. Dr. Estrin also has served as a consultant to the National Cancer Institute, a research assistant at Florida State University Florida State University, at Tallahassee; coeducational; chartered 1851, opened 1857. Present name was adopted in 1947. Special research facilities include those in nuclear science and oceanography. in Tallahassee, Fla., and as a chemist at Clairol Research Laboratories in Stamford, Conn. He received his doctorate in Physical-Organic Chemistry from Florida State University and is Regulatory Affairs Certified (RAC) by the Regulatory Affairs Professional Society. He serves on the board of The National Museum for Health & Medicine Foundation, The Institute for Advancement of Medical Communication and Discovery Pharmaceuticals, Inc., a company he co-founded in 1990. Dr. Estrin is a member of the Editorial Advisory Boards of the Medical Device Approval Letter and The Validation Consultant. Chantal Pharmaceutical Corporation has executive offices, telemarketing and warehouse facilities in Los Angeles, with a laboratory in Kaiserslautern, Germany. In addition to marketing the Chantal Ethocyn Skin Care Line, the company is engaged in the research and development of androgen mediated disorders such as acne, hirsutism Hirsutism Definition Excessive growth of facial or body hair in women is called hirsutism. Description Hirsutism is not a disease. The condition usually develops during puberty and becomes more pronounced as the years go by. , male pattern baldness male pattern baldness n. A progressive, diffuse loss of scalp hair in men that begins in the twenties or early thirties, depends on the presence of the androgenic hormone testosterone, and is caused by a combination of genetic and hormonal factors. , benign prostate hypertrophy hypertrophy (hīpûr`trəfē), enlargement of a tissue or organ of the body resulting from an increase in the size of its cells. Such growth accompanies an increase in the functioning of the tissue. and the treatment of certain cancers. CONTACT: Martin E. Janis & Company, Inc. Bev Jedynak, 312/943-1100 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion